Sime Armoyan Sells 100,000 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUDGet Rating) insider Sime Armoyan sold 100,000 shares of the business’s stock in a transaction on Friday, July 29th. The shares were sold at an average price of C$5.80, for a total transaction of C$580,110.00. Following the completion of the sale, the insider now directly owns 11,504,478 shares in the company, valued at approximately C$66,738,627.33.

Knight Therapeutics Trading Down 2.2 %

Shares of Knight Therapeutics stock opened at C$5.45 on Thursday. The firm has a market capitalization of C$624.70 million and a PE ratio of -99.09. The company has a debt-to-equity ratio of 5.64, a current ratio of 2.73 and a quick ratio of 2.05. The company’s fifty day moving average price is C$5.40 and its two-hundred day moving average price is C$5.39. Knight Therapeutics Inc. has a 52-week low of C$5.03 and a 52-week high of C$5.85.

Knight Therapeutics (TSE:GUDGet Rating) last posted its earnings results on Thursday, May 12th. The company reported C($0.02) earnings per share for the quarter, topping the consensus estimate of C($0.04) by C$0.02. The firm had revenue of C$63.81 million during the quarter, compared to the consensus estimate of C$52.80 million. On average, analysts expect that Knight Therapeutics Inc. will post -0.02 EPS for the current year.

Knight Therapeutics Company Profile

(Get Rating)

Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma.

Recommended Stories

Insider Buying and Selling by Quarter for Knight Therapeutics (TSE:GUD)

Want More Great Investing Ideas?

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.